

<b>1</b>	<b>Details of the person discharging managerial responsibilities</b>	
a)	Name	<i>Michael Engsig</i>
b)	Position	<i>Chief Executive Officer</i>
<b>2</b>	<b>Reason for notification</b>	
a)	Initial notification/ Amendment	<i>Initial</i>
<b>3</b>	<b>Details of issuer</b>	
a)	Name	<i>Nykode Therapeutics ASA</i>
b)	LEI	<i>254900UKQHYZJD22017</i>
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	<i>Shares in Nykode Therapeutics ASA (ISIN: NO0010714785)</i>
b)	Nature of the transaction	<i>Acquisition of shares</i>
c)	Price(s) and volume(s)	<p><b>Price(s)</b> NOK 17.10</p> <p><b>Volume</b> 9,850</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p><b>Price</b> NOK 17.10</p> <p><b>Volume</b> 9,850</p> <p><b>Total amount</b> NOK 168,435</p>
e)	Date of the transaction	<i>31.10.2023</i>
f)	Place of the transaction	<i>XOSL - Oslo Stock Exchange</i>